# EDGAR Filing Document

**Accession Number:** 0001365916
**File Stem:** 0001365916-23-000027
**Filing Date:** 2023-3
**Character Count:** 5532
**Document Hash:** c828636d48096d9337c4085b9b8ff24e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001365916-23-000027.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0001365916-23-000027

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230317

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMYRIS, INC.
- **CENTRAL INDEX KEY:** 0001365916
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL ORGANIC CHEMICALS [2860]
- **IRS NUMBER:** 550856151
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34885
- **FILM NUMBER:** 23757161

**BUSINESS ADDRESS:**
- **STREET 1:** 5885 HOLLIS STREET, SUITE 100
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 510-450-0761

**MAIL ADDRESS:**
- **STREET 1:** 5885 HOLLIS STREET, SUITE 100
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMYRIS BIOTECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20060613

?xml version="1.0" ? amrs-20230317

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

 

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**____________________**

Date of report (Date of earliest event reported): **March 17, 2023**

**Amyris, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34885** | **55-0856151** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **5885 Hollis Street, Suite 100,** | **Emeryville,** | **CA** | **94608** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

---

| | |
|:---|:---|
| **(510)** | **450-0761** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

 <br> (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | AMRS | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 17, 2023, the Company entered into a second amendment ("Amendment") to the Share Purchase Agreement ("Share Purchase Agreement") related to Aprinnova, LLC ("Aprinnova"), dated as of December 15, 2022, by and among the Company, Nikko Chemicals Co., Ltd. and Nippon Surfactant Industries, Co., Ltd. Pursuant to the Amendment, the parties agreed to extend the closing of the Share Purchase Agreement until April 17, 2023 (the "Closing Date"), upon which closing the Company will hold 99% of the outstanding membership interests in Aprinnova. The Company agreed that the interest accruing on the amounts set forth in Section 2.1(b) and (c) of the Share Purchase Agreement since February 14, 2023 will continue to accrue through the Closing Date.

The foregoing is only a brief description of the material terms of the Amendment, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the Amendment that will be filed as an exhibit to the Company's quarterly report on Form 10-Q for the quarterly period ended March 31, 2023.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>**  | **<u>Description</u>**  |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **AMYRIS, INC.** |
| Date: March 23, 2023 | By: | /s/ Han Kieftenbeld |
|  |  | Han Kieftenbeld |
|  |  | Chief Financial Officer |

---